PHA、CD3、与IL-2协同诱导PBMC过继免疫治疗恶性脑胶质瘤的实验研究

目的 提高人脑胶质瘤过继免疫治疗的效果，探索治疗脑胶质瘤的新途径。方法 用植物血凝素（PHA）、抗CD3单抗（CD3）和IL－2共同诱导人外周血单个核细胞（PBMC），诱导，扩增新型抗胶质瘤效应细胞PHA－CD3AK细胞，并与CD3AK细胞在某些生物学方面进行了比较。结果 两组效应细胞增殖曲线均于第6天达高峰，峰值可见，PHA－CD3AK细胞＞CD3AK（P＜0．05）；PHA－CD3AK细胞扩增倍数明显高于CD3AK细胞（P＜0．05）；两组效应细胞于培养的第6、8、10天所测得的杀伤胶质瘤细胞BT325活性可见，PHA－CD3AK细胞＞CD3AK细胞（P＜0．05）。结论 PHA、CD3和IL－2具有协同增强作用，使PHA－CD3AK细胞成为较CD3AK细胞增殖能力、杀伤活性更强的免疫效应细胞、且IL－2用量减少，为胶质瘤的过继免疫治疗打下了理论基础。

Experimental study on adoptive immunotherapy for malignant glioma with peripheral blood mononuclear cells(PBMC) Induced by PHA, CD3 and IL-2

Objective　To investigate a new clinical therapeutic approach for adoptive immunotherapy as malignant gliomas. Methods　In this study, a new type of killer cells, named PHA-CD3AK cells was induced by means of costimulating peripheral blood mononuclear cells with phytohemagglutinim (PHA), anti-CD3 monoclonal antibody (CD3) and Interleukin-2(IL-2), Its biological characteristics were compared with the control group, named CD3AK cells, induced by means of stimulating PBMC with CD3 and IL-2.Results　Both PHA-CD3AK cells and CD3AK cells, performed the highest proliferation during the 6th day of culture. It is obvious that the amount of proliferation of PHA-CD3 cells is higher than that of CD3AK cells P＜0.05). The actual multiplication fold of the former is much more than that of the control group. Moreover, PHA-CD3AK cells gained an advantage over the control group in cytotoxicity against malignant glioma cells (BT325) during the 6th, 7th and 8th day of cuture (P＜0.05). Conclusions　As a new type of killer cells, PHA-CD3AK cells have some advantages over the control group CD3AK cells in proliferation, cytotoxicity against BT325, and the utilizing amount of IL-2, indicating the synergistic enhancing role of PHA, CD3 and IL-2. The application of PHA-CD3AK cells might open a new prospect to clinical therapeutic approach for maligant gliomas.